Linagliptin-Metformin Linagliptin-Metformin Stada 2,5 Mg/500 Mg Filmtabletta

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Linagliptin-Metformin Linagliptin-Metformin Stada 2,5 Mg/500 Mg Filmtabletta (Metformin Hydrochloride, Linagliptin)

Q: What is Linagliptin‑Metformin Stada used for?

Linagliptin‑Metformin Stada is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, usually as part of a comprehensive plan that includes diet, exercise, and other antidiabetic agents when needed.

Q: How does linagliptin work in this combination?

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which raises levels of incretin hormones such as GLP‑1. This enhances glucose‑dependent insulin release and reduces glucagon secretion, helping to lower post‑prandial glucose.

Q: What is the usual dose of this medication?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy.

Q: Is Linagliptin‑Metformin safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been established. Clinicians usually consider alternative treatments for pregnant or nursing women unless the benefits outweigh potential risks.

Q: How do I order Linagliptin‑Metformin from GNH India?

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does this product compare with other antidiabetic options?

Compared with separate tablets of linagliptin and metformin, the fixed‑dose combination simplifies the regimen, reduces pill burden and may improve adherence, while delivering the same pharmacologic actions of a DPP‑4 inhibitor plus a biguanide.

Q: What are the storage requirements for this tablet?

Store the film‑coated tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light.

Q: How is Linagliptin‑Metformin administered?

The tablet is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole; do not split, crush, or chew unless advised otherwise.

Q: What are the most serious risks associated with this medication?

Serious concerns include lactic acidosis (especially in patients with renal or hepatic impairment), pancreatitis, severe hypersensitivity reactions, and hypoglycaemia when combined with insulin or sulfonylureas.

Q: Who should not use Linagliptin‑Metformin?

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or those with acute or chronic metabolic acidosis, including lactic acidosis, should avoid this medication.

Linagliptin, the active ingredient in Linagliptin‑Metformin Stada 2,5 Mg/500 Mg Filmtabletta, is a DPP‑4 inhibitor presented as a 2.5 mg/500 mg film‑coated tablet for oral use. It treats type 2 diabetes mellitus in adults, often in combination with diet and exercise.

GNH India supplies Linagliptin‑Metformin Stada 2,5 Mg/500 Mg Filmtabletta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, targeting hyperglycaemia through complementary mechanisms.

Type 2 diabetes mellitus: improves glycaemic control as part of combination therapy.
Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c.
Fixed‑dose combination therapy: simplifies regimen and enhances patient adherence.

How It Works

Linagliptin selectively inhibits dipeptidyl peptidase‑4, raising endogenous GLP‑1 levels and promoting glucose‑dependent insulin secretion. Metformin hydrochloride suppresses hepatic gluconeogenesis, reduces intestinal glucose absorption, and increases peripheral insulin sensitivity, together providing additive glucose‑lowering effects in type 2 diabetes.

Side Effects

Common Side Effects

Nausea: mild to moderate gastrointestinal discomfort.
Diarrhoea: loose stools, usually transient.
Headache: mild tension‑type pain.
Nasopharyngitis: upper respiratory symptoms.
Dizziness: occasional light‑headedness.
Abdominal pain: mild cramping.

Serious or Rare Side Effects

Lactic acidosis: rare but life‑threatening metabolic disturbance.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe hypersensitivity: rash, angioedema, or anaphylaxis.
Hepatic failure: signs of liver dysfunction.
Hypoglycaemia: when combined with insulin or sulfonylureas.
Renal impairment: worsening kidney function may occur.

Precautions & Warnings

Before initiating therapy, evaluate patient-specific risk factors and monitor regularly.

Renal function assessment: check eGFR prior to start and periodically thereafter.
Hepatic impairment: use with caution in patients with liver disease.
Risk of lactic acidosis: avoid in severe renal or hepatic dysfunction.
Pregnancy and lactation: safety not established; consider alternative agents.
Drug interactions: review concomitant medicines that affect renal clearance or increase hypoglycaemia risk.
Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Linagliptin/Metformin may interact with several medicines; monitor and adjust therapy as needed.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated.
Co‑administration with other DPP‑4 inhibitors: duplicate therapy risk.
Use with high‑dose metformin in hepatic failure: heightened lactic acidosis risk.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: increased hypoglycaemia potential.
Iodinated contrast media: temporary renal function decline; monitor renal parameters.

Frequently Asked Questions

Linagliptin‑Metformin Stada is prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, usually as part of a comprehensive plan that includes diet, exercise, and other antidiabetic agents when needed.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which raises levels of incretin hormones such as GLP‑1. This enhances glucose‑dependent insulin release and reduces glucagon secretion, helping to lower post‑prandial glucose.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy.

Safety in pregnancy and lactation has not been established. Clinicians usually consider alternative treatments for pregnant or nursing women unless the benefits outweigh potential risks.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with separate tablets of linagliptin and metformin, the fixed‑dose combination simplifies the regimen, reduces pill burden and may improve adherence, while delivering the same pharmacologic actions of a DPP‑4 inhibitor plus a biguanide.

Store the film‑coated tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light.

The tablet is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole; do not split, crush, or chew unless advised otherwise.

Serious concerns include lactic acidosis (especially in patients with renal or hepatic impairment), pancreatitis, severe hypersensitivity reactions, and hypoglycaemia when combined with insulin or sulfonylureas.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or those with acute or chronic metabolic acidosis, including lactic acidosis, should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.